X hits on this document

81 views

0 shares

0 downloads

0 comments

34 / 39

Figure 1: Regimen Market Shares, 1993-2005

100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%

Outside option

5-FU/LV

Oxaliplatin + 5-FU/LV

Irinotecan + 5-FU/LV Irinotecan

Capecitabine

Bevacizumab + oxaliplatin + 5-FU/LV

1993

1995

1997

1999

2001

2003

2005

Source: IntrinsiQ and SEER. Market share is measured as the percentage of colon cancer patients who are treated with drugs that are treated with a specific regimen.

Document info
Document views81
Page views81
Page last viewedSun Dec 04 09:06:09 UTC 2016
Pages39
Paragraphs850
Words10609

Comments